RBM28在肝细胞癌组织中的表达及临床意义

Expression and clinical significance of RBM28 in hepatocellular carcinoma tissues

目的:分析RBM28在肝细胞癌组织中的表达水平及与患者临床病理特征的相关性,探讨RBM28在肝细胞癌中的临床意义。方法:通过生物信息学分析RBM28在肝细胞癌组织和正常组织中的表达水平以及与患者预后的关系。采用免疫组织化学和蛋白质免疫印迹法检测RBM28在肝细胞癌组织和癌旁正常组织中的表达水平,并分析其与患者临床病理特征的相关性。此外,还使用qRT-PCR法检测RBM28 mRNA在组织中的表达水平。结果:经过生物信息学分析,发现RBM28蛋白在肝细胞癌组织中的表达水平明显高于正常组织,并且高表达组患者的总生存期(OS)明显低于低表达组患者。进一步实验分析发现,RBM28蛋白及mRNA在肝细胞癌组织中的表达水平均高于癌旁正常组织(P<0.01)。此外,RBM28蛋白的表达与肝细胞癌患者的年龄、性别、微血管侵犯、甲胎蛋白和乙肝无关,但与肿瘤大小和TNM分期有关(P<0.05)。结论:RBM28在肝细胞癌组织中高表达,与肿瘤大小、TNM分期和预后不良相关,有望成为肝细胞癌潜在的分子标志物及治疗的新靶点。

Objective:To investigate the clinical significance of RBM28 in hepatocellular carcinoma by analyzing its expression levels in tumor tissues and its correlation with clinicopathological features of patients.Methods:The expression levels of RBM28 in hepatocellular carcinoma tissues and normal tissues were analyzed by bioinformatics,and the relationship with patient prognosis of patients was analyzed.Immunohistochemistry and protein immunoblotting were used to detect the expression level of RBM28 in hepatocellular carcinoma tissues and adjacent normal tissues,and its correlation with clinicopathological features of patients was analyzed.In addition,the expression level of RBM28 mRNA in tissues was detected using qRT-PCR.Results:The results of bioinformatics analysis indicated that the expression level of RBM28 protein in hepatocellular carcinoma tissues was significantly higher than in normal tissues,and the overall survival(OS)of patients with high expression was significantly lower than that of patients with low expression.Further experimental analysis demonstrated that both RBM28 protein and mRNA were highly expressed in hepatocellular carcinoma tissues compared to adjacent normal tissues(P<0.01).Additionally,the expression of RBM28 protein was not associated with age,gender,microvascular invasion,alpha-fetoprotein and HBV,but was significantly correlated with tumor size and TNM stage(P<0.05).Conclusion:RBM28 is highly expressed in hepatocellular carcinoma tissues and is associated with tumor size,TNM stage,and poor prognosis.It has the potential to serve as a molecular biomarker and a novel therapeutic target for hepatocellular carcinoma.